ReviewTherapeutic advances in gastroenterology2014
Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide.
Review in Therapeutic advances in gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Discovery, biosynthesis, and bioactivities of peptidic natural products from marine sponges and sponge-associated bacteria.Natural product reports · 2025Review
- Update on the Treatment of Autonomic Disorders.Current treatment options in neurology · 2025Article
- Progress in the Stereoselective Synthesis Methods of Pyrrolidine-Containing Drugs and Their Precursors.International journal of molecular sciences · 2024Review
- Effect of Organic Solvents on the Activity, Stability and Secondary Structure of asclepain cI, Using FTIR and Molecular Dynamics Simulations.The protein journal · 2024Article
- Structural insight into guanylyl cyclase receptor hijacking of the kinase-Hsp90 regulatory mechanism.eLife · 2023Article
- Structural insight into guanylyl cyclase receptor hijacking of the kinase-Hsp90 regulatory mechanism.bioRxiv : the preprint server for biology · 2023Article
- Enzymatic synthesis of new antimicrobial peptides for food purposes.Frontiers in microbiology · 2023Article
- Oral Phyto-thymol ameliorates the stress induced IBS symptoms.Scientific reports · 2020Article
- Cellular mechanism for herbal medicine Junchoto to facilitate intestinal ClJournal of natural medicines · 2018Article
- Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivityWorld journal of gastroenterology · 2018Article
- Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.Therapeutic advances in gastroenterology · 2018Review
- New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.Therapeutic advances in gastroenterology · 2016Review
- Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Pharmacology · 2015Review
- Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Frontiers in psychiatry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents had limited ability to address the complexity of symptoms inherent to the syndrome. The development of linaclotide provides a physiologically sound approach to treatment of the multiple symptoms of IBS-C. Clinical trials demonstrate the efficacy of linaclotide, and a platform to better understand the symptomatology of IBS-C. Based on recent clinical evidence, linaclotide should be considered for patients with IBS-C because it improves abdominal pain and bowel symptoms. In phase III trials, linaclotide met the US Food and Drug Administration responder endpoint with a number needed to treat (NNT) of 5.1-7.9, and European Medicines Agency coprimary endpoints at 12 weeks with a NNT of 4.39-7.69, and at 26 weeks with a NNT of 4.93-5.68. It is safe and effective, with diarrhea reported as the most common adverse effect, which leads to discontinuation of the medication in approximately 5% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.